Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
2008
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
2008
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
2000
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
Crucial Involvement of Tumor-Associated Neutrophils in the Regulation of Chronic Colitis-Associated Carcinogenesis in Mice
2012
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer
2012
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Therapeutic cancer vaccines: are we there yet?
2010
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Prognostic Markers in Resected Non–Small-Cell Lung Cancer: An Patients with 5 Year Follow-Up
1999
Chemotherapy for small cell lung cancer
2003
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy
2012
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America
2002
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594
2001
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited
2009
Neurologic disorders in 432 consecutive patients with small cell lung carcinoma
2004
Lung Cancer
2008 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Coordinated regulation of myeloid cells by tumours
2012 Standout
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
2004
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
2004
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Lung cancer: current therapies and new targeted treatments
2016 Standout
Global cancer statistics
2011 Standout
The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends
2008
Clinical Survival Predictors in Patients With Advanced Cancer
2000
Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis
2010 Standout
Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results
2001
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03
2009
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Chemotherapy as treatment of primary and recurrent small cell lung cancer
2001
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Neutrophil/lymphocyte ratio and its association with survival after complete resection in non–small cell lung cancer
2008
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases
2008
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer
2005
MicroRNA signatures in human cancers
2006 Standout
Double-Cycle, High-Dose Ifosfamide, Carboplatin, and Etoposide Followed by Peripheral Blood Stem-Cell Transplantation for Small Cell Lung Cancer
2005
Microtubules as a target for anticancer drugs
2004 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
2001
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
2004
Neutrophils in cancer: neutral no more
2016 Standout
Gene-expression profiles predict survival of patients with lung adenocarcinoma
2002 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Small-cell lung cancer
2005
HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert–Eaton myasthenic syndrome
2004
Systemic Inflammatory Response Predicts Prognosis in Patients with Advanced-Stage Colorectal Cancer
2008
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
A palliative accelerated irradiation regimen for advanced non–small-cell lung cancer VS. conventionally fractionated 60 GY: results of a randomized equivalence study
2000
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Hepatocellular carcinoma
2022 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity
2006
Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma
2012
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
Chemotherapy of advanced non-small cell lung cancer
1999
Cancer statistics in China, 2015
2016 Standout
Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer.
2012
Screening for Small-Cell Lung Cancer: A Follow-Up Study of Patients With Lambert-Eaton Myasthenic Syndrome
2008
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
2008
Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review
2000
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
mice: Multivariate Imputation by Chained Equations inR
2011 Standout
Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval
2005
Global cancer statistics, 2012
2015 Standout
Prognostic Value of Thoracic FDG PET Imaging After Treatment for Non-Small Cell Lung Cancer
2000
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma
2009
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of O Van Cutsem being referenced
Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.
1996
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
1995
Prognostic factors for patients with small cell lung carcinoma
2000
Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC)
1996
Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer
1994
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics
2001
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party
1997
A randomized trial comparing in small cell lung cancer (SCLC) induction chemotherapy by ifosfamide and etoposide with adriamycin (IVA) or epirubicine (IVE): An European lung cancer working party report
1993
A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC)
2006